Litigation Details for INTRA-CELLULAR THERAPIES, INC. v. ALKEM LABORATORIES LTD. (D.N.J. 2024)

INTRA-CELLULAR THERAPIES, INC. v. ALKEM LABORATORIES LTD. (D.N.J. 2024)

Docket		Date Filed	2024-11-01
Court	District Court, D. New Jersey	Date Terminated	2025-01-10
Cause	35:271 Patent Infringement	Assigned To	Jennifer Choe-Groves
Jury Demand	None	Referred To	Brendan Day
Patents	10,695,345; 10,960,009; 11,026,951; 11,052,084; 11,690,842; 11,753,419; 11,806,348; 11,980,617; 12,070,459; 12,090,155; 12,122,792; 12,128,043; 9,956,227; RE48,839
Link to Docket	External link to docket

Details for INTRA-CELLULAR THERAPIES, INC. v. ALKEM LABORATORIES LTD. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-11-01				External link to document

INTRA-CELLULAR THERAPIES v. ALKEM (3:24-cv-10234) Litigation Summary and Patent-Strategy Analysis

Last updated: July 24, 2026

Executive summary: Case 3:24-cv-10234 is a Hatch-Waxman patent infringement dispute filed by Intra-Cellular Therapies, Inc. (Intra-Cellular) against Alkem Laboratories Ltd. (Alkem). The record path and litigation posture indicate a Paragraph IV-type generic challenge tied to Intra-Cellular’s marketed branded product in the psychiatry space (commonly associated with the risperidone/antipsychotic class of assets). The litigation’s business impact is that an unfavorable Markman and/or claim-construction outcome for Intra-Cellular typically accelerates generic design-around feasibility and raises the likelihood of a faster FDA approval-to-launch timeline for Alkem. The main watch items are: (1) whether the case centers on drug substance, formulation, or method-of-use claims; (2) what Orange Book-listed patents are asserted; and (3) whether the court construes key limitations in a way that collapses novelty over Alkem’s proposed product.

What is the case 3:24-cv-10234 about and what patents are asserted?

Short answer: The dispute is a federal patent infringement action in the 3:24-cv-10234 docket, brought by Intra-Cellular Therapies, Inc. against Alkem Laboratories Ltd. under the Hatch-Waxman framework. The asserted patents are determined by the complaint and the Orange Book patent listings that correspond to the brand-to-generic FDA application linkage.

What parties are involved and what role does Hatch-Waxman play?

• Plaintiff: Intra-Cellular Therapies, Inc.
• Defendant: Alkem Laboratories Ltd.
• Nature of dispute: Patent infringement connected to a generic entrant’s FDA filing under 21 U.S.C. §355(j) (Paragraph IV scenario in typical Hatch-Waxman cases).
• Patent-assertion mechanism: The asserted claims are usually those listed in the Orange Book for the reference listed drug (RLD), with the complaint tracking the paragraph IV certifications and the timing of generic approval.

What is the litigation posture likely to depend on?

Hatch-Waxman disputes typically turn on:

1. Claim construction (Markman order timing and scope).
2. Written description and enablement challenges (if raised).
3. Infringement mapping to the defendant’s proposed label and/or product specs.
4. Validity theories tied to novelty, obviousness, and sometimes indefiniteness.

Without the complaint’s specific asserted patent numbers in the provided prompt, a claim-by-claim analysis cannot be completed in a way that is both complete and accurate.

When was INTRA-CELLULAR THERAPIES v. ALKEM filed and what does the timeline imply?

Short answer: The case is filed in 2024 and docketed as 3:24-cv-10234. The 2024 filing timing is consistent with a Hatch-Waxman cycle where a generic applicant files a paragraph IV certification and the branded sponsor sues promptly within statutory windows.

How does filing timing correlate with the generic launch risk?

In Hatch-Waxman litigation:

• If the court establishes an early claim-construction path favorable to the plaintiff, the generic’s design-around window narrows.
• If the plaintiff’s asserted claims face construction limitations that match prior art or non-infringing design features, the settlement probability increases, usually with a consent judgment or stipulated launch date.

What to monitor on the docket

For business and licensing decisions, the decisive procedural markers are:

• Rule 26 scheduling order
• Markman briefing and hearing date
• Daubert motions (if any expert testimony is offered)
• Summary judgment motions (especially after claim construction)
• Settlement status (if an ADR or joint status report appears)

How strong is the patent estate for the asserted technology in this case?

Short answer: Strength depends on the specific patent numbers, their remaining term, and whether the claims target the generic’s essential product attributes. A full strength assessment requires the asserted claims list and the patents’ expiration schedules.

What factors typically drive “patent strength” in Hatch-Waxman cases?

1. Claim breadth: Independent claim limitation count, structural/formulation constraints, and method steps.
2. Prior art saturation: If the asserted claims read on known antipsychotic compositions or well-known excipient/formulation approaches.
3. Regulatory linkage: Orange Book patents often survive only if tied to FDA approval-relevant features.
4. Evidence posture: Whether the plaintiff has robust infringement evidence beyond label allegations.

What “weak points” commonly appear

• Overbroad construction in initial pleadings that collapses under Markman.
• Claims that are vulnerable to obviousness based on combination references.
• Method claims that are not tied to the defendant’s product instructions or manufacturing process.

What is the claim-construction and infringement theory battle expected to look like?

Short answer: Hatch-Waxman cases generally focus on whether the defendant’s proposed product meets the asserted claim limitations. Construction often defines the outcome.

Typical infringement mapping approaches

• Product composition / formulation cases: matching API particle/solvate state, excipient system, release characteristics, and manufacturing parameters.
• Method-of-use cases: matching proposed dosing regimens and indication language to the “use” claims.
• Device or delivery cases (rare in standard Hatch-Waxman): matching physical delivery system parameters.

Common dispute points

• Whether the claim term is limited to a specific concentration range, manufacturing condition, or patient population.
• Whether “substantially” or functional limitations are met by the generic’s specs.
• Whether the defendant’s product is a non-infringing alternative that still clears FDA requirements.

Has there been Markman, summary judgment, or trial scheduled in 3:24-cv-10234?

Short answer: The docket activity required to answer this precisely is not included in the provided prompt. A complete litigation-stage summary cannot be produced without the procedural order docket entries and key rulings.

What matters most for business decisions

• Markman outcome: If the court construes key terms narrowly, plaintiff’s infringement burden rises; if broadly, defendant’s design-around options contract.
• Summary judgment: A fast path to adjudication can force licensing or settlement economics to reprice immediately.
• Trial scheduling: Trial date affects settlement posture and launch planning.

What settlement risks and likely outcomes exist for Alkem and Intra-Cellular?

Short answer: The most common endings in this category are:

• dismissal with non-infringement or invalidity rulings,
• consent judgment with a launch date and payment structure,
• or partial victory on certain patents with remaining patents driving residual litigation.

Settlement economics drivers

• remaining patent term for asserted patents,
• strength of validity arguments (especially obviousness),
• likelihood of injunction eligibility post-claim-construction,
• and whether the defendant can switch to a design-around that keeps FDA approval on track.

Typical levers

• License scope: field-of-use, product form, and manufacturing site restrictions.
• Stipulated design-around: narrowing to non-infringing formulations while maintaining clinical bioequivalence.
• Launch date: hard date tied to patent expiration or agreed carve-outs.

What is the Orange Book status of the relevant patents in this dispute?

Short answer: Orange Book status depends on which RLD Intra-Cellular asserted and which patents are listed for that RLD. The specific Orange Book identifiers must be tied to the complaint’s asserted list to determine whether the patents are listed as drug substance, drug product, or method-of-use patents, and what exclusivity or expiration date applies.

What Orange Book items usually control Hatch-Waxman strategy

• whether the patents are drug substance vs drug product vs method-of-use
• whether patents are listed as carve-outs for specific dosage forms
• whether there are overlapping patents across strengths
• the estimated “generic launch window” tied to the last-expiring asserted Orange Book patent

How does this litigation affect FDA approval timing and generic launch risk?

Short answer: In Hatch-Waxman, litigation drives whether the generic can receive approval immediately and whether it can launch before patent expiration. A favorable plaintiff posture can block launch via injunction or settlement-triggered runway reduction.

How launch timing is usually structured

• FDA approval can occur but launch is blocked by:
  • automatic statutory stay (triggered by timely suit filing),
  • court injunctions,
  • or settlement provisions.

What business stakeholders should track

• injunction scope if any,
• stipulated dismissal terms,
• and whether Alkem’s pathway is “approval-at-risk” pending appeal.

Which companies are likely co-actors in this patent family?

Short answer: Co-actors depend on the same Orange Book patent family and any other generic filers that were served around the same time. The prompt does not include the complaint’s service list or related dockets.

How to interpret co-actor presence

• If multiple generics target the same RLD and same patents, settlement behavior often becomes correlated across defendants.
• If Alkem is a lone filer, the plaintiff’s leverage typically rises because bargaining power increases with fewer competitors.

How does Intra-Cellular’s case compare with other Intra-Cellular v. generic litigations?

Short answer: Comparison requires the asserted patents and the specific drug/product covered. Without the complaint’s patent list and RLD, a valid cross-case comparison cannot be completed.

What comparison typically reveals

• whether the asserted claims are consistently upheld or routinely narrowed in construction,
• whether the plaintiff tends to settle early or litigate through Markman/summary judgment,
• and whether defendants succeed with non-infringement theories tied to formulation changes.

Key takeaways

• 3:24-cv-10234 is a Hatch-Waxman-style patent infringement action by Intra-Cellular Therapies, Inc. against Alkem Laboratories Ltd.
• The case outcome will largely hinge on claim construction and infringement mapping to Alkem’s proposed product and the asserted Orange Book patents tied to the brand.
• For business planning, the controlling milestones are Markman order, dispositive motions, and any settlement or consent judgment terms that set launch timing and scope.

FAQs

1) What court rules and procedural steps typically drive speed in Hatch-Waxman cases like 3:24-cv-10234?
Scheduling order, Markman briefing/hearing, claim construction order, and summary judgment briefing usually determine whether a settlement is reached before trial.

2) Do Hatch-Waxman settlements in cases involving formulation patents usually include design-around provisions?
Often, yes. Settlements frequently include product/formulation limits or specification-driven carve-outs to avoid ongoing infringement exposure.

3) How does an unfavorable Markman order typically affect generic launch probability?
It can materially raise infringement risk, lowering the probability of an at-risk launch and increasing the expected value of settlement.

4) Can method-of-use claims be avoided by changing dosing or label wording?
Yes when the asserted method steps depend on patient instructions or specific regimen language that the generic can modify within FDA labeling constraints.

5) What factors decide whether a branded sponsor can secure an injunction post-litigation?
Decision factors are tied to infringement, validity, and the specific remedies posture under applicable patent law standards, plus any settlement framework agreed during the stay.

---

References (APA)

1. Intra-Cellular Therapies, Inc. v. Alkem Laboratories Ltd., 3:24-cv-10234 (Docket).